Extended-Spectrum Beta-Lactamase Detection with Different Panels for Automated Susceptibility Testing and with a Chromogenic Medium
暂无分享,去创建一个
W. König | I. Tammer | B. König | F. Layer | B König | W König | J Färber | K-A Moder | F Layer | I Tammer | J. Färber | K.-A. Moder
[1] R. Ramphal,et al. Extended-Spectrum β-Lactamases and Clinical Outcomes: Current Data , 2006 .
[2] Y. Glupczynski,et al. Evaluation of a New Selective Chromogenic Agar Medium for Detection of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae , 2006, Journal of Clinical Microbiology.
[3] P. Nordmann,et al. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. , 2002, The Journal of antimicrobial chemotherapy.
[4] Armand Paauw,et al. Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 Automated Instruments for Detection of Extended-Spectrum Beta-Lactamases in Multiresistant Escherichia coli and Klebsiella spp , 2002, Journal of Clinical Microbiology.
[5] S. Covan,et al. Two-Center Collaborative Evaluation of Performance of the BD Phoenix Automated Microbiology System for Identification and Antimicrobial Susceptibility Testing of Gram-Negative Bacteria , 2006, Journal of Clinical Microbiology.
[6] D. Mack,et al. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection. , 2004, The Journal of antimicrobial chemotherapy.
[7] J. Barry,et al. Comparative evaluation of the VITEK 2 Advanced Expert System (AES) in five UK hospitals. , 2003, The Journal of antimicrobial chemotherapy.
[8] H. Goossens,et al. International Prospective Study of Klebsiella pneumoniae Bacteremia: Implications of Extended-Spectrum -Lactamase Production in Nosocomial Infections , 2004, Annals of Internal Medicine.
[9] M. Frosch,et al. Comparative evaluation of a new Vitek 2 system for identification and antimicrobial susceptibility testing of Streptococcus pneumoniae , 2006, European Journal of Clinical Microbiology and Infectious Diseases.
[10] J. Lucet,et al. Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] C. O'hara. Evaluation of the Phoenix 100 ID/AST System and NID Panel for Identification of Enterobacteriaceae, Vibrionaceae, and Commonly Isolated Nonenteric Gram-Negative Bacilli , 2006, Journal of Clinical Microbiology.
[12] D. Mack,et al. Comparison of BDPhoenix and VITEK2 automated antimicrobial susceptibility test systems for extended-spectrum beta-lactamase detection in Escherichia coli and Klebsiella species clinical isolates. , 2003, Diagnostic microbiology and infectious disease.
[13] D. Livermore,et al. CTX-M: changing the face of ESBLs in the UK. , 2005, The Journal of antimicrobial chemotherapy.
[14] P. Vandamme,et al. Comparative Evaluation of the BD Phoenix and VITEK 2 Automated Instruments for Identification of Isolates of the Burkholderia cepacia Complex , 2002, Journal of Clinical Microbiology.
[15] Maurizio Sanguinetti,et al. Characterization of Clinical Isolates of Enterobacteriaceae from Italy by the BD Phoenix Extended-Spectrum β-Lactamase Detection Method , 2003, Journal of Clinical Microbiology.
[16] N. Hanson,et al. Detection of Plasmid-Mediated AmpC β-Lactamase Genes in Clinical Isolates by Using Multiplex PCR , 2002, Journal of Clinical Microbiology.
[17] L. Bret,et al. Chromosomally Encoded AmpC-Type β-Lactamase in a Clinical Isolate of Proteus mirabilis , 1998, Antimicrobial Agents and Chemotherapy.
[18] Yehuda Carmeli,et al. Utility of the VITEK 2 Advanced Expert System for Identification of Extended-Spectrum β-Lactamase Production in Enterobacter spp , 2006, Journal of Clinical Microbiology.
[19] J. Ariza,et al. Epidemiology and Successful Control of a Large Outbreak Due to Klebsiella pneumoniae Producing ExtendedSpectrum β-Lactamases , 1998, Antimicrobial Agents and Chemotherapy.
[20] J. Bartlett. International prospective study of klebsiella pneumoniae bacteremia: Implications of extended-spectrum β-lactamase production in nosocomial infections , 2004 .
[21] Kenneth S. Thomson,et al. Comparison of Phoenix and VITEK 2 Extended-Spectrum-β-Lactamase Detection Tests for Analysis of Escherichia coli and Klebsiella Isolates with Well-Characterized β-Lactamases , 2007, Journal of Clinical Microbiology.
[22] N. Woodford,et al. CTX-M: changing the face of ESBLs in Europe. , 2006, The Journal of antimicrobial chemotherapy.
[23] Victor L. Yu,et al. Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology Laboratory , 2001, Journal of Clinical Microbiology.
[24] M. Bonora,et al. Evaluation of the VITEK 2 System for Identification and Antimicrobial Susceptibility Testing of Medically Relevant Gram-Positive Cocci , 2002, Journal of Clinical Microbiology.
[25] R. Ramphal,et al. Extended-spectrum beta-lactamases and clinical outcomes: current data. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] Harald Seifert,et al. Detection of Extended-Spectrum Beta-Lactamases among Enterobacteriaceae by Use of Semiautomated Microbiology Systems and Manual Detection Procedures , 2007, Journal of Clinical Microbiology.
[27] Marianne Abele-Horn,et al. Validation of VITEK 2 Version 4.01 Software for Detection, Identification, and Classification of Glycopeptide-Resistant Enterococci , 2006, Journal of Clinical Microbiology.
[28] M. Jackson,et al. Management of multidrug-resistant organisms in health care settings, 2006. , 2007, American journal of infection control.
[29] S. Mitsuhashi,et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens , 1983, Infection.